Breaking News

EU Fines Three Banks in Swiss Franc Libor Antitrust Cases
Tweet TWEET

Echo Therapeutics Presents Positive Clinical Trial Results of the Symphony® tCGM System at the 42nd Critical Care Congress

 Echo Therapeutics Presents Positive Clinical Trial Results of the Symphony®
                tCGM System at the 42nd Critical Care Congress

PR Newswire

PHILADELPHIA, Jan. 22, 2013

PHILADELPHIA, Jan. 22, 2013 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony^® Transdermal Continuous
Glucose Monitoring (tCGM) System as a non-invasive, wireless, transdermal
continuous glucose monitoring system, presented an expanded analysis of data
collected from the clinical study of Echo's Symphony tCGM System in critically
ill patients at Tufts Medical Center in Boston, MA. The data were presented
during Display and Professor Walk Rounds on Sunday, January 20, 2013 at the
Society of Critical Care Medicine's 42^nd Critical Care Congress.

(Logo:http://photos.prnewswire.com/prnh/20120801/NE50071LOGO)

The poster, entitled "Accuracy of a Novel Non-Invasive Transdermal Continuous
Glucose Monitor in Critically Ill Patients," presented by the principal
investigator, Stanley A. Nasraway, M.D., FCCM, provided data from fifteen (15)
patients who were undergoing elective cardiac surgery. The patients' glucose
levels were monitored continuously for 24 hours. The key findings include:

  oUsing 570 Symphony tCGM glucose readings paired with reference blood
    glucose measurements, the Mean Absolute Relative Difference (MARD) was
    12.3%.
  oThe Clarke Error Grid (CEG) analysis showed that 81.7% of the readings
    appeared in the grid's A zone with the remaining 18.3% percent falling in
    the B zone. The grid's A zone represents results that are the most
    clinically accurate and results in the B zone are considered clinically
    acceptable.
  oThe Continuous Glucose-Error Grid analysis (CG-EGA) showed that 99.6% of
    the readings were clinically accurate (A) and 0.0% were benign (B) errors
    with a combined A+B of 99.6%.
  o94.4% of the calculated CGM rates were within +/-1 mg/dL/min of the
    reference rate and 99.6% were within +/-2 mg/dL/min.

"We value this opportunity for engagement with the critical care community to
share this Symphony study data with key opinion leaders in the field as we
prepare for upcoming European and FDA regulatory trials," said David Walton,
Echo Therapeutics' Vice President of Marketing and Commercial Development. "As
we explore collaboration opportunities, we are very encouraged by the
increasing awareness of our developmental, non-invasive continuous glucose
monitoring technology."

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive,
wireless, transdermal continuous glucose monitoring system. Our target is
patients who could benefit from glucose monitoring in the hospital setting,
including critical care. Significant opportunity also exists for patients
with diabetes to use Symphony in the outpatient setting. Echo is also
developing its needle-free skin preparation component of Symphony, the
Prelude^® SkinPrep System, as a platform technology to enhance drug delivery
of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Echo's ongoing
studies, including the safety and efficacy of Echo's Symphony tCGM System, the
failure of future development and preliminary marketing efforts related to
Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure
additional commercial partnering arrangements, risks and uncertainties
relating to Echo's and its partners' ability to develop, market and sell
diagnostic and transdermal drug delivery products based on its skin permeation
platform technologies, including the Symphony tCGM and Prelude SkinPrep
Systems, the availability of substantial additional equity or debt capital to
support its research, development and product commercialization activities,
and the success of its research, development, regulatory approval, marketing
and distribution plans and strategies, including those plans and strategies
related to its Symphony tCGM and Prelude SkinPrep Systems. These and other
risks and uncertainties are identified and described in more detail in Echo's
filings with the Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the year ended December 31,
2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K.
Echo undertakes no obligation to publicly update or revise any forward-looking
statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104
colimpio@echotx.com

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at http://www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.

Website: http://www.sontra.com
 
Press spacebar to pause and continue. Press esc to stop.